Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Pamela N MunsterAndrew E GreensteinGini F FlemingErkut Hasan BorazanciManish R SharmaJoseph M CustodioIulia Cristina TudorHristina I PashovaStacie Peacock ShepherdAndreas GrauerJasgit C SachdevPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The observed preclinical, clinical, and GR-specific pharmacodynamic responses demonstrate that selective GR modulation with relacorilant combined with nab-paclitaxel may promote chemotherapy response and is tolerable. Further evaluation of this combination in tumor types responsive to taxanes is ongoing.